2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid isopropylamide | 258831-74-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid isopropylamide
• 英文别名: 5-isopropylaminosulfonylindolin-2-one；5-Isopropylaminosulfonyl-2-oxindole；2-oxo-N-propan-2-yl-1,3-dihydroindole-5-sulfonamide
• CAS: 258831-74-2
• 化学式: C₁₁H₁₄N₂O₃S
• mdl: MFCD10566468
• 分子量: 254.31
• InChiKey: ZDZVVSVVBTXHJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid isopropylamide 在 sodium hydroxide 、 甲烷磺酸 、 水 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.16h， 生成 2-[(5-isopropylsulfamoyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)amino]benzoic acid
  参考文献：
  名称：

  WO2007/117699

  摘要：

  公开号：
• 作为产物：
  描述：

  2-吲哚酮 在 氯磺酸 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid isopropylamide
  参考文献：
  名称：

  Design and synthesis of aminopropyl tetrahydroindole-based indolin-2-ones as selective and potent inhibitors of Src and Yes tyrosine kinase

  摘要：

  A novel series of substituted 3-[3-(aminopropyl)-4,5,6,7-tetrahydro-1H-indol-2-ylmethylene]-1,3-dihydro-indole-2-ones was discovered as potent inhibitors of the non-receptor tyrosine kinase Src and Yes. A structure-activity relationship was developed in order to optimize their potency and selectivity. Syntheses of these compounds are also described herein. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.069

文献信息

• Indolinone derivatives as protein kinase/phosphatase inhibitors
  申请人：——

  公开号：US20020052369A1

  公开（公告）日：2002-05-02

  The present invention relates to certain 2-indolinone compounds which modulate the activity of protein kinases (“PKs”) and phosphatases. The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

  本发明涉及调节蛋白激酶（“PKs”）和磷酸酶活性的某些2-吲哚酮化合物。因此，本发明的化合物在治疗与异常PK活性相关的疾病方面是有用的。还公开了包含这些化合物的药物组合物、利用包含这些化合物的药物组合物治疗疾病的方法以及制备它们的方法。
• Combination therapy for the treatment of cancer
  申请人：Pharmacia Corporation

  公开号：US20030216410A1

  公开（公告）日：2003-11-20

  The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.

  本发明涉及使用蛋白酪氨酸激酶抑制剂与环氧合酶抑制剂，特别是环氧合酶-2选择性抑制剂，联合治疗或预防肿瘤性疾病的方法。
• Pyrrole substituted 2-indolinone protein kinase inhibitors
  申请人：——

  公开号：US20020156292A1

  公开（公告）日：2002-10-24

  The present invention relates to pyrrole substituted 2 -indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯替代的2-吲哚酮化合物及其药学上可接受的盐，这些化合物调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面具有用处。
• Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
  申请人：Sugen. Inc.

  公开号：US20030100555A1

  公开（公告）日：2003-05-29

  The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯替代的2-吲哚酮化合物及其药学上可接受的盐，这些化合物调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面具有用处。
• 3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof
  申请人：Tang Feng

  公开号：US20100160318A1

  公开（公告）日：2010-06-24

  3-pyrrolo[b]cyclohexylene-2-dihydro-indolinone derivatives of formula (I) or their pharmaceutically acceptable salts and uses thereof. The intermediates of formula (II) for preparing the above compounds. The bioassay shows that the above compounds and their pharmaceutically acceptable salts can modulate the activity of protein kinases (PKs), inhibit the activity of tyrosine kinases (PTKs) and inhibit many kinds of tumor cells as well as.

  公式（I）的3-吡咯[ b ]环己烯-2-二氢吲哚酮衍生物或其药用盐及其用途。用于制备上述化合物的公式（II）的中间体。生物测定表明，上述化合物及其药用盐可以调节蛋白激酶（PKs）的活性，抑制酪氨酸激酶（PTKs）的活性，并抑制多种类型的肿瘤细胞。